85-1403-79　Resistin, Human, Control Peptide (ADSF, Adipose Tissue-Specific Secretory Factor, FIZZ3, Found in Inflammatory Zone) 100ug　R1585-22I

特徴

• Control Peptide for R1585-22G (antiserum) and R1585-22F (affinity purified)
• Resistance to insulin characterizes type 2 diabetes, the most common form of diabetes. There is a strong link between type 2 diabetes and obesity, as most patients tend to be obese. Thiozolidinediones (TZDs), a new class of anti-diabetic drugs, enhances target-tissue sensitivity to insulin. A screen of genes down regulated by TZD in adipocyte led to the discovery of a new protein hormone called resistin (for resistance to insulin). Resistin, specifically produced and secreted by adipocyte, is present at elevated levels in the blood of obese animals, and is down regulated by fasting and anti-diabetic drugs. Antibody to resistin stimulated glucose uptake and improved insulin sensitivity in obese mice. Some other protein related to resistin has been called resistin-related molecules (RELM-alpha and beta). Resistin family of proteins was also identified as proteins (FIZZ1-3, for Found in Inflammatory zone) involved in allergy and inflammation.
• Resistin is also described as serine/cysteine-rich Adipocyte-Specific Secretory Factor (ADSF or FIZZ3). Resistin (pre peptide length: human 108 aa; mouse/rat 114 aa; mol wt ~12.5kD) is characterized by the presence of a hydrophobic signal peptide that is cleaved before its secretion. Resistin proteins show ~55% homology in human and mouse. It is 45-55% related to RELM-alpha/FIZZ1/PMNG1 (Parasite-induced Macrophage Novel Gene 1). RELM-alpha mRNA was most abundant in white adipose tissue. It is also expressed in mammary tissue with significant fat pads. Unlike resistin, RELM-alpha is not expressed in 3T3-L1 adipocyte or in preadipocytes. It is also found in heart, lung and tongue, where resistin is absent. In mice, RELM-alpha/FIZZ1 is found at low levels in a subset of bronchial epithelial cells and in non-neuronal cells adjacent to neurovascular bundles in the peribronchial stroma, and in the wall of the large and small bowel.
• Applications:Suitable for use in ELISA and Antibody Blocking. Not suitable for use in Western Blot due to low molecular weight. Other applications not tested.
• Recommended Dilution:Antibody Blocking: 5-10ug per 1ul R1585-22G (antiserum) or per 1ug R1585-22F (affinity purified antibody)
• ELISA: 50-100ng/well
• Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4°C for short-term only. For long-term storage, store at -20°C. Aliquots are stable for at least 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.